



PHILIP MORRIS INTERNATIONAL

**PRESS RELEASE**

Investor Relations:  
Stamford, CT: +1 (203) 905 2413  
Lausanne: +41 (0)58 242 4666  
Email: [InvestorRelations@pmi.com](mailto:InvestorRelations@pmi.com)

Media: David Fraser  
Lausanne: +41 (0)58 242 4500  
Email: [David.Fraser@pmi.com](mailto:David.Fraser@pmi.com)

**PHILIP MORRIS INTERNATIONAL TO HOST WEBCAST OF  
2023 INVESTOR DAY**

STAMFORD, CONNECTICUT – September 20, 2023 – Philip Morris International Inc. (PMI) (NYSE: PM) will host a live video webcast of presentations and Q&A at its 2023 Investor Day, which will be held at its Operations Center in Lausanne, Switzerland, on September 28, 2023.

The presentations and Q&A session will be webcast live on Thursday, September 28, 2023, at approximately 9:55 a.m. CET and conclude at approximately 5:00 p.m. CET. The webcast will be available at [www.pmi.com/2023InvestorDay](http://www.pmi.com/2023InvestorDay). A copy of the slides will be made available on the same webpage, where a transcript will also be posted following the event.

The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at [www.pmi.com/irapp](http://www.pmi.com/irapp).

An archive of the webcast will be available until Friday, October 27, 2023.

**Philip Morris International: Delivering a Smoke-Free Future**

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies' *IQOS* and *ZYN* brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI's *IQOS* Platform 1 devices and consumables and Swedish Match's *General* snus as Modified Risk Tobacco Products (MRTPs). As of June 30, 2023, PMI's smoke-free products were available for sale in 80 markets, and PMI estimates that approximately 19.4 million adults around the world had already switched to *IQOS* and stopped smoking. Smoke-free products accounted for approximately 35.4% of PMI's total second-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit [www.pmi.com](http://www.pmi.com) and [www.pmiscience.com](http://www.pmiscience.com).